Grant / Resource Support Mechanisms
The NIH has three programs to assist investigators with their translational research: the Division of Cancer Prevention (DCP) PREVENT Cancer Preclinical Drug Development Program, the National Center for Advancing Translational Sciences (NCATS) Bridging Interventional Development Gaps (BrIDGs) program, and the National Cancer Institute’s Experimental Therapeutics (NExT) program.
NCI describes PREVENT as being its pipeline for preclinical development of new cancer-preventing interventions and biomarkers towards clinical trials.
- Applications are accepted twice per year.
- PREVENT is not a grant or contract program. The NCI may allocate various resources and expertise toward implementation and development.
- Current favored areas of focus are anti-inflammatory approaches to cancer prevention and immunoprevention.
Critical resources for development of new therapeutic agents are made available on a competitive basis through NCATS BrIDGs program.
- Receipt dates for the BrIDGs program are scheduled one to two times per year.
- BrIDGs is not a grant program. Instead of receiving grant funds, successful applicants gain access to the government’s contract resources, as well as assistance with establishing and implementing a product development plan. Applicants may request as many services as are needed to generate sufficient data for an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA).
- The output of BrIDGs activities, in the form of research material and data, will be made fully available to the applicant organization in support of their IND application and Phase I clinical trials.
The NExT program is a partnership between NCI’s Division of Cancer Treatment and Diagnosis (DCTD) and the Center for Cancer Research (CCR) that consolidates NCI’s anticancer drug discovery and development resources into a goal-driven therapeutics pipeline.
- NExT accepts applications three times per year.
- NExT is not a grant program. Instead of receiving grant funds, successful applicants gain access to the scientific capabilities and resources of the NCI. The NCI will partner with successful applicants to move new anticancer drugs (small molecules, biologics) and imaging agents towards clinical evaluation and registration.
- Resources fall under three categories: early-stage drug discovery, late-stage drug discovery and clinical drug development. Early-stage resourcing is done via the NCI's Chemical Biology Consortium (CBC) and requires the investigator to become a signatory to the CBC Participants Agreement.
Links to Additional Translational Research Funding Resources